Abbott Laboratories Trading Volume Drops 47% Ranking 57th Despite Stock Price Surge

Abbott Laboratories reported a trading volume of $1.28 billion on July 21, 2025, marking a 47.28% decrease from the previous day. The company's trading volume ranked 57th among all stocks traded that day. Abbott's stock price has been on an upward trend, rising 0.61% and marking two consecutive days of gains, with a total increase of 3.24% over the past two days.

Abbott Laboratories has announced that it will be hosting a conference call to discuss its second-quarter financial results. The call is scheduled for July 21, 2025, at 8:30 AM Eastern Time. During the call, the company's management team will provide an overview of the company's financial performance for the quarter, as well as discuss its outlook for the remainder of the year.

Abbott Laboratories has received approval from the U.S. Food and Drug Administration (FDA) for its new FreeStyle Libre 3 system. The system is a continuous glucose monitoring device that is designed to help people with diabetes manage their blood sugar levels more effectively. The approval is expected to drive sales growth for the company in the coming quarters.

Abbott Laboratories has announced that it will be acquiring Alere, a leading provider of rapid diagnostic tests, for $5.8 billion. The acquisition is expected to expand Abbott's diagnostic capabilities and strengthen its position in the global diagnostics market. The deal is subject to regulatory approval and is expected to close in the second half of 2025.